RECRUITING

Neuroblastoma Biology Study

Talk to us

Conditions

Neuroblastoma

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Medical scientists want to find better ways to treat neuroblastoma and to find ways to prevent the tumor from growing back. To do this, they need more information about the characteristics of neuroblastoma cells. Therefore, they want to study samples of neuroblastoma tissues and neuroblastoma and normal cells in the blood and bone marrow that may be related to the growth of neuroblastoma cells. Doctors and other medical scientists also want to find better ways to detect and measure neuroblastoma to improve the ability to follow the response of tumor cells to therapy.

Official Title

N2004-05: Neuroblastoma Biology Study

Quick Facts

Study Start:2011-07
Study Completion:2099-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT01587300

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:31 Days to 99 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Patients must be greater than or 31 days of age.
  2. * Patients must have had a diagnosis of high risk neuroblastoma either by histological verification of neuroblastoma and/or demonstration of tumor cells in the bone marrow with increased urinary catecholamines.
  3. * All patients with refractory or recurrent high risk neuroblastoma at NANT institutions are eligible regardless of disease status (including no measurable or evaluable tumor) as long as they undergo a disease evaluation and appropriate samples are submitted.
  4. * Additionally, all patients with high risk neuroblastoma without relapse treated at a NANT institution are eligible if undergoing a disease evaluation, as long as Children's Oncology Group specimens are prioritized.
  1. * There are no exclusion criteria on this study.

Contacts and Locations

Study Contact

Araz Marachelian, MD
CONTACT
323-361-5687
amarachelian@chla.usc.edu

Principal Investigator

Shahab Asgharzadeh, MD
STUDY_CHAIR
Children's Hospital Los Angeles

Study Locations (Sites)

Children's Hospital Los Angeles
Los Angeles, California, 90027-0700
United States
Lucille Salter Packer Children's Hospital, Stanford University
Palo Alto, California, 94305
United States
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, 94115
United States
Children Hospital of Colorado
Aurora, Colorado, 80045
United States
AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus
Atlanta, Georgia, 30322
United States
University of Chicago, Comer Children's Hospital
Chicago, Illinois, 60637
United States
Children's Hospital Boston
Boston, Massachusetts, 02115
United States
C.S Mott Children's Hospital
Ann Arbor, Michigan, 48109
United States
University of North Carolina
Chapel Hill, North Carolina, 27599
United States
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229-3039
United States
Nationwide Children's Hospital
Columbus, Ohio, 43205
United States
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104-4318
United States
St. Jude Children's Research Hospital
Memphis, Tennessee, 38105
United States
University of Texas Southwestern
Dallas, Texas, 75235
United States
Cook Children's Medical Center - Fort Worth
Fort Worth, Texas, 76104
United States
Seattle Children's Hospital
Seattle, Washington, 98105
United States

Collaborators and Investigators

Sponsor: New Approaches to Neuroblastoma Therapy Consortium

  • Shahab Asgharzadeh, MD, STUDY_CHAIR, Children's Hospital Los Angeles

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2011-07
Study Completion Date2099-12

Study Record Updates

Study Start Date2011-07
Study Completion Date2099-12

Terms related to this study

Additional Relevant MeSH Terms

  • Neuroblastoma